Last reviewed · How we verify

Edward Lain, MD — Portfolio Competitive Intelligence Brief

Edward Lain, MD pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Amzeeq 4% Topical Foam Amzeeq 4% Topical Foam marketed Tetracycline antibiotic Bacterial 30S ribosomal subunit; matrix metalloproteinases Dermatology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Air Force Specialized Hospital, Cairo, Egypt · 1 shared drug class
  2. Beijing Tiantan Hospital · 1 shared drug class
  3. Chinese University of Hong Kong · 1 shared drug class
  4. Clinica Universidad de Navarra, Universidad de Navarra · 1 shared drug class
  5. Darier · 1 shared drug class
  6. Galderma R&D · 1 shared drug class
  7. Generic (originally Pfizer) · 1 shared drug class
  8. ANRS, Emerging Infectious Diseases · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Edward Lain, MD:

Cite this brief

Drug Landscape (2026). Edward Lain, MD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/edward-lain-md. Accessed 2026-05-15.

Related